Spanish nutraceuticals firm Puleva Biotech has posted a 3% jump in nine-month net profits to €1.4m (US$1.8m), boosted by a 50% sales jump to €5.34m. Gross operating profit leapt 27% to €2.7m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company, a unit of food major Ebro Puleva, said sales of its key functional-food compound Omega3 rose sharply in the third quarter, boosted by demand from Ebro Puleva’s Omega3 dairy products. New sales and third-party research contracts in Spain, Europe and North America, also boosted fortunes.
Puleva Biotech said capital expenditures rose (unspecified) against those in the year-ago period to pay for factory upgrades and launch new investigation projects.
